Solid Biosciences (SLDB) Gains from Sales and Divestitures (2018 - 2026)

Solid Biosciences has disclosed Gains from Sales and Divestitures across 8 years of filings, most recently posting $518546.0 for Q1 2026.

• Gains from Sales and Divestitures for Q1 2026 came in at $518546.0, up 109.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $518546.0 (up 109.12% YoY), and the FY2025 annual result was $434314.0, up 29.27% from the prior year.
• Gains from Sales and Divestitures came in at $518546.0 for Q1 2026 at Solid Biosciences, up from $434314.0 in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $518546.0 in Q1 2026 to a low of $183951.0 in Q4 2023.
• The 4-year median for Gains from Sales and Divestitures is $280159.0 (2025), against an average of $310251.0.
• Across the five-year window, Gains from Sales and Divestitures grew 21.53% in 2025 and jumped 109.12% in 2026, its largest moves.
• Solid Biosciences' Gains from Sales and Divestitures stood at $183951.0 in 2023, then surged by 82.65% to $335981.0 in 2024, then climbed by 29.27% to $434314.0 in 2025, then gained by 19.39% to $518546.0 in 2026.
• The last three Gains from Sales and Divestitures figures came in at $518546.0 (Q1 2026), $434314.0 (Q4 2025), and $323487.0 (Q3 2025), per Business Quant data.